Universität zu Köln

Hoenigl, M., Lewis, R., van de Veerdonk, F. L., Verweij, P. E. and Cornely, O. A. (2022). Liposomal amphotericin B-the future. J. Antimicrob. Chemother., 77. S. 21 - 35. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2091

Full text not available from this repository.

Abstract

Advances in medicine have led to a growing number of people with compromised or suppressed immune systems who are susceptible to invasive fungal infections. In particular, severe fungal infections are becoming increasingly common in ICUs, affecting people within and outside of traditional risk groups alike. This is exemplified by the emergence of severe viral pneumonia as a significant risk factor for invasive pulmonary aspergillosis, and the recognition of influenza-associated pulmonary aspergillosis and, more recently, COVID-19-associated pulmonary aspergillosis. The treatment landscape for haematological malignancies has changed considerably in recent years, and some recently introduced targeted agents, such as ibrutinib, are increasing the risk of invasive fungal infections. Consideration must also be given to the risk of drug-drug interactions between mouldactive azoles and small-molecule kinase inhibitors. At the same time, infections caused by rare moulds and yeasts are increasing, and diagnosis continues to be challenging. There is growing concern about azole resistance among both moulds and yeasts, mandating continuous surveillance and personalized treatment strategies. It is anticipated that the epidemiology of fungal infections will continue to change and that new populations will be at risk. Early diagnosis and appropriate treatment remain the most important predictors of survival, and broad-spectrum antifungal agents will become increasingly important. Liposomal amphotericin B will remain an essential therapeutic agent in the armamentarium needed to manage future challenges, given its broad antifungal spectrum, low level of acquired resistance and limited potential for drug-drug interactions.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hoenigl, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lewis, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED van de Veerdonk, F. L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Verweij, P. E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, O. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-684756
DOI:	10.1093/jac/dkac353
Journal or Publication Title:	J. Antimicrob. Chemother.
Volume:	77
Page Range:	S. 21 - 35
Date:	2022
Publisher:	OXFORD UNIV PRESS
Place of Publication:	OXFORD
ISSN:	1460-2091
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INVASIVE PULMONARY ASPERGILLOSIS; RESISTANT CANDIDA-AURIS; DRUG-DRUG INTERACTIONS; AZOLE RESISTANCE; FUNGAL-INFECTIONS; MOLD INFECTIONS; CLINICAL CHARACTERISTICS; TRANSPLANT RECIPIENTS; SURVEILLANCE PROGRAM; TARGETED THERAPIES Multiple languages Infectious Diseases; Microbiology; Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68475